NYSE: CNMD · Medical Devices
CONMED (CNMD) fair value and price range
As of 14 Nov 2026, Faircurve's model values CONMED (CNMD) at $50.43 a share. The stock last closed at $49.35, which puts the model's fair value 2.2% above the price. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say how likely the fair value is to be right.
Revalued . Price is the close of 16 Nov 2026. CONMED Corporation.
The report adds the live price, the chart against the range the options market prices, the next earnings date and the analysts' consensus. No account needed.
This week, in three parts
What happenedThe run of 14 Nov 2026 moved the fair value from $63.48 to $50.43 (-20.6%). The multiple the model anchors on moved, lowering the fair value: most of the move.
What the model makes of itThe price of $49.35 is 2.2% below it. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say how likely the fair value is to be right.
What's nextNext report on 27 Jan 2027. Options prices imply a move of about 14% either way over the next month. The next weekly run is on Saturday 21 Nov 2026.
What price range does the model give CNMD?
The calibrated range for CNMD over 63 trading days is $41.92 to $58.58. It sits around the last close, and its width comes from the volatility that CNMD's own options imply (49% a year), calibrated weekly against realised prices (n = 8,038 past valuations, refreshed 14 Nov 2026). Ranges built this way held the price 60% of the time at this horizon. The fair value is the model's opinion and rides beside the range. It is not the centre of it.
The model's own simulated range, from the 20th to the 80th percentile of its runs, is $21.86 to $93.38. In 50% of the simulations the fair value came out above the price the model ran on.
Faircurve Insights · 14 Nov 2026
CONMED Corporation is a medical technology enterprise. It develops, produces and distributes surgical instruments and related apparatus for a variety of surgical procedures around the world.
Faircurve's model gave CONMED a fair value of $50.43 a share on 14 Nov 2026, the midpoint of 2,000 simulations. The previous run, on 7 Nov 2026, gave $63.48, so the fair value moved -20.6%. The model says the multiple it anchors on moved, lowering the fair value, and that this is most of the move. The calibrated range over 63 trading days is $42.97 to $60.05, built around the price from the volatility the stock's own options imply. Ranges built this way held the price 60% of the time at this horizon. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say whether the fair value is right.
CONMED scores 63 out of 100 on the model's overall quality measure, a composite of six factors scored against comparable companies. Capital discipline stands out at 96, with net buybacks at 3.3% of market value against a peer median of 0.0%. Profitability scores 66, with ROIC of 6.3% against a peer median of -0.7%. The balance sheet scores 27, with net debt at 3.63x EBITDA. The model compares CONMED with Enovis Corporation, Integra LifeSciences Holdings Corporation, UFP Technologies, Inc., Artivion, Inc. and Neogen Corporation, each with its own fair value on the site.
Written from the figures on this page for the 14 Nov 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.
The Global Pulse
Faircurve's note after each US session, in your inbox. No account needed.
When does CNMD report earnings, and how has the stock reacted?
CONMED's next earnings report is scheduled for 27 Jan 2027. Companies can move their dates.
On 16 Nov 2026, CNMD's 30 day implied volatility worked out to a move of about 14.3% over one month, in either direction. That is a size, not a direction.
Around its last 8 reports: what the options market priced, and what followed
Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across CNMD's last 8 reports, ignoring direction, was 4.5%.
How does CNMD score on business quality?
CONMED's overall quality score is 63 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.
| Factor | Score (0 to 100) | Headline measure | Peer median |
|---|---|---|---|
| ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend. | 66 | 6.3%ROIC | -0.7% |
| Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash). | 83 | 1.81xFCF / net income | |
| Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analysts' rating changes. | 38 | 5.2%Revenue growth, trailing | 4.1% |
| Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks. | 96 | 3.3%Net buybacks / market value | 0.0% |
| Balance sheetNet debt to EBITDA and interest coverage. | 27 | 3.63xNet debt / EBITDA | |
| StabilityDownside volatility of the EBITDA margin over the last five years. | 71 | 4.8 ptsEBITDA margin downside volatility, 5y | 15.3 pts |
How does CNMD compare with similar companies?
The companies in medical devices closest to CONMED in market value, each on the same model and the same date.
| Company | Last close | Model fair value | Gap | Model verdict |
|---|---|---|---|---|
| ENOV Enovis Corporation | $27.92 | $32.77 | +17.4% | Undervalued |
| TNDM Tandem Diabetes Care, Inc. | $18.48 | $21.89 | +18.5% | Low evidence grade |
| INSP Inspire Medical Systems, Inc. | $59.12 | $61.27 | +3.6% | Low evidence grade |
| IART Integra LifeSciences Holdings Corporation | $13.98 | $16.00 | +14.4% | Fairly valued |
| AHCO AdaptHealth Corp. | $7.73 | $7.47 | -3.4% | Low evidence grade |
| UFPT UFP Technologies, Inc. | $298.54 | $266.65 | -10.7% | Fairly valued |
| AORT Artivion, Inc. | $18.47 | $20.28 | +9.8% | Fairly valued |
| NEOG Neogen Corporation | $10.88 | $10.11 | -7.1% | Fairly valued |
What the comparable companies' multiples alone would give for CNMD, the peer-implied price, is $47.31 a share on this run. The fair value weighs that against the company's own multiple.
CONMED at a glance
CONMED Corporation functions as a medical technology enterprise, specializing in the global development, production, and distribution of surgical instruments and related apparatus for a variety of surgical procedures.
- Market value
- $1.5B
- Sector
- Healthcare
- Industry
- Medical Devices
- Revenue expected, next twelve months
- $1.4B
- Consensus revenue growth, next fiscal year
- -0.9%
- Analysts with estimates
- 4
- Beta to the US market
- 0.48
- First valued by Faircurve
- 11 Jul 2026
How the fair value is worked out: the model prices CONMED on the value of the whole business, debt included, against the operating profit analysts expect next year (forward EV/EBITDA), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.
What changed in the latest valuation?
On 7 Nov 2026 the model's fair value for CNMD was $63.48. As of 14 Nov 2026 it is $50.43, a change of -20.6%. The multiple the model anchors on moved, lowering the fair value: most of the move. The model revalues every stock it covers each week, and again after an earnings report.
Questions about CONMED's valuation
Is CONMED stock undervalued or overvalued?
Faircurve's model puts CNMD's fair value at $50.43 a share against a last close of $49.35, as of 14 Nov 2026. The model grades the evidence behind this valuation as low, so no verdict is shown. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say how likely the fair value is to be right.
What is CNMD's fair value?
$50.43 a share as of 14 Nov 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $21.86 to $93.38.
What price range does the model give CNMD?
$41.92 to $58.58 over 63 trading days. Ranges built this way held the price 60% of the time across 8,038 past valuations, refreshed 14 Nov 2026.
When does CONMED report earnings next?
The next report is scheduled for 27 Jan 2027. Companies can move their dates.
How much has CNMD moved on past earnings reports?
Across its last 8 reports the median two session move was 4.5%, ignoring direction. The largest was +11.9% around the report of 4 Nov 2026.
How confident is the model in this valuation?
The model's evidence grade for CNMD is low. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.
The model's own ideas on CNMD
The model holds no idea open on CNMD today. Signed-in readers see the rule each idea runs on, the floor and the exit level the model set and its time limit, and the model's closed ideas on CNMD with their outcomes. A free account is enough.